Glaxo to Get Up to $200 Million From U.S. for Biothreat Research

GlaxoSmithKline Plc (GSK), the U.K.’s largest drugmaker, will work with the U.S. government to develop antibiotics for resistant infections and bioterrorist threats in an agreement valued at as much as $200 million.

By Makiko Kitamura and Olivia Sterns

Full Story: http://www.businessweek.com/news/2013-05-22/glaxo-to-get-up-to-200-million-from-u-dot-s-dot-for-biothreat-research